# PK of Rivaroxaban in Bariatric Patients - Extension

> **NCT02832947** · PHASE1 · COMPLETED · sponsor: **Insel Gruppe AG, University Hospital Bern** · enrollment: 13 (actual)

## Conditions studied

- Prophylaxis of Venous Thromboembolism

## Interventions

- **DRUG:** Rivaroxaban 10 mg

## Key facts

- **NCT ID:** NCT02832947
- **Lead sponsor:** Insel Gruppe AG, University Hospital Bern
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02
- **Primary completion:** 2016-06
- **Final completion:** 2016-10
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2017-04-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02832947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02832947, "PK of Rivaroxaban in Bariatric Patients - Extension". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02832947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*